Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 12/20 | 0.56 |
| ▸ | ECE1 | P42892 | 1/20 | 0.55 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.55 |
| ▸ | GCGR | P47871 | 1/20 | 0.53 |
| ▸ | GIPR | P48546 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.52 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.51 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.50 |
| ▸ | CCKBR | P32239 | 2/20 | 0.50 |
| ▸ | CCKAR | P32238 | 1/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.50 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24625800 | 1.00 | GLP1R (0.56) | GLP1RECE1MUS81GCGRGIPR | |
| SCHEMBL12124805 | 0.94 | GLP1R (0.53) | GLP1RECE1MUS81GCGRGIPR | |
| SCHEMBL92822 | 0.90 | PRMT1 (0.55) | GLP1RECE1MUS81CXCR4ERBB2 | |
| SCHEMBL26236645 | 0.88 | GLP1R (0.46) | GLP1RECE1MUS81GCGRGIPR | |
| SCHEMBL8227196 | 0.86 | CCKAR (0.56) | GLP1RGCGRGIPRERBB2CCKBR | |
| SCHEMBL16690458 | 0.85 | GLP1R (0.46) | GLP1RECE1MUS81GCGRRXFP1 | |
| SCHEMBL29679760 | 0.81 | GLP1R (0.65) | GLP1RECE1MUS81RXFP1CCKBR | |
| SCHEMBL29679523 | 0.81 | GLP1R (0.69) | GLP1RECE1MUS81RXFP1CCKBR | |
| SCHEMBL10157514 | 0.81 | CCKBR (0.54) | ERBB2CCKBRCCKAROPRD1PRMT1 | |
| SCHEMBL26080290 | 0.81 | NPBWR1 (0.58) | GLP1RRXFP1CCKBRCCKAROPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2504353-B2 | LIPOPEPTIDE COMPOSITIONS AND RELATED METHODS | CUBIST PHARMACEUTICALS LLC (CH) | 2023-09-13 | — | — | EP | disclosed |
| US-7335726-B2 | Lipopeptide stereoisomers, methods for preparing same and useful intermediates | CUBIST PHARMACEUTICALS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7262268-B2 | Lipopeptide stereoisomers, methods for preparing same, and useful intermediates | CUBIST PHARMACEUTICALS, INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-20060223983-A1 | Lipopeptide stereoisomers, methods for preparing same and useful intermediates | CUBIST PHARMACEUTICALS, INC. | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223983-A1 | Lipopeptide stereoisomers, methods for preparing same and useful intermediates | NGLY1, LSS, NRDC | GLP1R 305/4885ECE1 3407/4885MUS81 676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.